Insulin-Sensiting Effects of Tumor Necrosis Factor Alpha Inhibitors in Rheumatoid Arthritis: a Systematic Review and Meta-Analysis.

Background: Rheumatoid arthritis (RA) has been associated with insulin resistance (IR), a well-established pathophysiological feature of type 2 diabetes (T2DM). Inconsistent literature evidence suggests that IR could be ameliorated by biological medications targeting TNF alpha. Objective: The aim of this systematic review was to evaluate the effect of TNF alpha inhibitors (TNFi) on IR in RA patients. Methods: We performed a systematic review in order to identify the available data on the effect of anti-TNF alpha medications on IR in RA patients. For this purpose, MedLine (via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL) and SCOPUS were searched up to December 2016. Results: The search strategy retrieved 209 individual records. Of these, only 12 articles were included in the systematic review. The pooled analysis under a random-effects model demonstrated a significant improvement of IR after treatment with TNFi quantified with the HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR), with a standardized difference in means (SDM) of -0.847 (95% CI: -1.278.-0.417, p < 0.0001). Heterogeneity across studies was high (Q = 65.00 with df = 9, p < 0.001, I-2 = 89.15%). Conclusion: Our meta-analysis suggests that TNF alpha blockade might improve IR in RA patients.